Washington: Hypertension treatment is associated with lower death rate and gain in life expectancy, a new study has found.
John B. Kostis and his colleagues from the UMDNJ-Robert Wood Johnson Medical School, New Brunswick, N.J., conducted a study to examine the effect of blood pressure (BP) lowering on long-term outcomes like life expectancy.
They obtained long-term mortality data for participants in the Systolic Hypertension in the Elderly Program (SHEP) trial, which was a randomised, placebo-controlled, clinical trial designed to assess the effect of antihypertensive drug treatment (chlorthalidone) in reducing the risk of stroke in patients with isolated systolic hypertension.
Recruitment for SHEP was between March 1985 and January 1988. After the end of a 4.5-year randomised phase of the SHEP trial, all participants were advised to receive active therapy.
The time interval between the beginning of recruitment and the ascertainment of death (December 2006) was approximately 22 years (21 years 10 months).
Of the 4,736 participants enrolled in the SHEP trial, 2,365 (49.9 percent) were randomised to active treatment therapy and 2,371 (50.1 percent) were randomised to placebo. The average age of participants was 72 years, 57 percent were women, and 14 percent were black.
At the end of follow-up, 2,851 of the 4,736 randomised patients (60.2 percent) had died, with 1,416 deaths (59.9 percent) in the active treatment group and 1,435 deaths (60.5 percent) in the placebo group.
The researchers found that both life expectancy and time to the 70th percentile survival at the end of follow-up were longer for the SHEP participants who were randomised to the active group compared with those randomised to the placebo group.
Life expectancy gain at 22 years was 158 days for cardiovascular death and 105 days for death from all causes. The gain in life expectancy free from cardiovascular death corresponds with 1 day (0.89 days) gained per month of treatment.
For all-cause mortality, the gain in life expectancy from 1 month of antihypertensive drug treatment was estimated at a half day (0.59 days).
They also found that the active treatment group was associated with higher survival free from cardiovascular death compared with the placebo group.
“Reporting that each month of antihypertensive therapy was associated with 1 day prolongation of life expectancy free from cardiovascular death is a strong message that may result in increased patient adherence to drug therapy and decrease the degree of therapeutic inertia by health care providers,” the authors said.
The study has been recently published in JAMA.